{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/237684538"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Meaningful factors which could cause actual results to differ include, but are not limited to, NICE's decision regarding the ILUVIEN STA, uncertainty as to Alimera's ability to commercialize (alone or with others), and market acceptance of, ILUVIEN in Germany, the United Kingdom and France, and other factors discussed in the Risk Factors\" and Management's Discussion and Analysis of Financial Con" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "biospace.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/392086439"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/237684538" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/274579393"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/237684538" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/157081021"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/237684538"] } } }
